FY2022 Earnings Forecast for Karyopharm Therapeutics Inc Issued By Wedbush (KPTI)

Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Research analysts at Wedbush issued their FY2022 earnings per share estimates for Karyopharm Therapeutics in a report issued on Thursday. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of $2.60 for the year.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%.

Other equities analysts also recently issued reports about the stock. Royal Bank of Canada reaffirmed a “buy” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Robert W. Baird reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Jefferies Group reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, October 13th. Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Karyopharm Therapeutics currently has a consensus rating of “Buy” and an average target price of $17.33.

Karyopharm Therapeutics (NASDAQ KPTI) opened at $12.28 on Monday. The stock has a market cap of $579.38, a price-to-earnings ratio of -4.63 and a beta of 4.09. Karyopharm Therapeutics has a twelve month low of $7.48 and a twelve month high of $14.63.

In other news, SVP Christopher Brett Primiano sold 4,958 shares of the stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total value of $55,777.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Kauffman sold 10,000 shares of the stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $10.09, for a total transaction of $100,900.00. Following the completion of the sale, the chief executive officer now owns 522,143 shares of the company’s stock, valued at $5,268,422.87. The disclosure for this sale can be found here. Insiders sold 72,000 shares of company stock valued at $730,969 over the last quarter. Company insiders own 14.71% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in KPTI. Vanguard Group Inc. increased its position in Karyopharm Therapeutics by 31.1% during the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after purchasing an additional 384,658 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Karyopharm Therapeutics by 753.5% during the third quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock worth $3,342,000 after buying an additional 271,208 shares during the period. Northern Trust Corp boosted its stake in Karyopharm Therapeutics by 36.5% during the second quarter. Northern Trust Corp now owns 405,374 shares of the company’s stock worth $3,668,000 after buying an additional 108,369 shares during the period. Iguana Healthcare Management LLC boosted its stake in Karyopharm Therapeutics by 33.3% during the third quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock worth $4,392,000 after buying an additional 100,000 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in Karyopharm Therapeutics by 396.0% during the third quarter. Nationwide Fund Advisors now owns 105,664 shares of the company’s stock worth $1,160,000 after buying an additional 84,362 shares during the period. Hedge funds and other institutional investors own 60.92% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “FY2022 Earnings Forecast for Karyopharm Therapeutics Inc Issued By Wedbush (KPTI)” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/29/fy2022-earnings-forecast-for-karyopharm-therapeutics-inc-issued-by-wedbush-kpti.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply